Nuformix PLC Posting of Annual Report and Notice of AGM (4720U)
01 August 2022 - 9:13PM
UK Regulatory
TIDMNFX
RNS Number : 4720U
Nuformix PLC
01 August 2022
1 August 2022
Nuformix plc
("Nuformix" or the "Company" or the "Group")
Posting of Annual Report and Notice of AGM
Nuformix plc (LSE: NFX), a pharmaceutical development company
targeting unmet medical needs in fibrosis and oncology via drug
repurposing, announces that the Annual Financial Report for the
year ended 31 March 2022 (the "Annual Financial Report 2022") and
the 2022 Notice of Annual General Meeting ("AGM") are today being
posted to its shareholders:
A full pdf version of the Annual Financial Report 2022 together
with the Notice of Annual General Meeting is available for download
from the Investor Information section on the Company's website
www.nuformix.com .
The Annual Financial Report 2022 will be filed with the
Registrar of Companies in due course and copies can be obtained
from the Company Secretary, SGH Company Secretaries Limited, 60
Gracechurch Street, London, EC3V 0HR.
The Annual General Meeting will be held on 25 August 2022 at
2.00 pm at the offices of Shakespeare Martineau, 6(th) floor, 60
Gracechurch Street, London, EC3V 0HR.
Enquiries:
Nuformix plc
Dr Julian Gilbert, Non-executive Via IFC Advisory
Chairman
Stanford Capital Partners Limited
Tom Price / Patrick Claridge (Corporate
Finance) +44 (0) 20 3650 3650
John Howes (Corporate Broking) +44 (0) 20 3650 3652
IFC Advisory Limited
Tim Metcalfe +44 (0) 20 3934 6630
Zach Cohen nuformix@investor-focus.co.uk
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing. The
Company aims to use its expertise in discovering, developing and
patenting novel drug forms, with improved physical properties, to
develop new products in new indications that are, importantly,
differentiated from the original (by way of dosage, delivery route
or presentation), thus creating new and attractive commercial
opportunities. Nuformix has a pipeline of preclinical assets with
potential for significant value and early licensing
opportunities.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOAFLFLLTLILIIF
(END) Dow Jones Newswires
August 01, 2022 07:13 ET (11:13 GMT)
Nuformix (LSE:NFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nuformix (LSE:NFX)
Historical Stock Chart
From Jul 2023 to Jul 2024